Ventyx Biosciences, Inc.’s (NASDAQ:VTYX) Lock-Up Period To End on April 19th

Ventyx Biosciences’ (NASDAQ:VTYX – Get Rating) lock-up period is set to end on Tuesday, April 19th. Ventyx Biosciences had issued 9,472,656 shares in its public offering on October 21st. The total size of the offering was $151,562,496 based on an initial share price of $16.00. After the end of Ventyx Biosciences’ lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

VTYX has been the topic of several research reports. Canaccord Genuity Group initiated coverage on shares of Ventyx Biosciences in a report on Thursday, March 31st. They set a “buy” rating on the stock. Zacks Investment Research upgraded shares of Ventyx Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, March 26th. Canaccord Genuity Group initiated coverage on shares of Ventyx Biosciences in a report on Thursday, March 31st. They set a “buy” rating and a $30.00 price objective on the stock. Finally, Oppenheimer initiated coverage on shares of Ventyx Biosciences in a report on Tuesday, February 1st. They set an “outperform” rating and a $30.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Ventyx Biosciences presently has an average rating of “Buy” and a consensus price target of $38.00.

NASDAQ VTYX opened at $13.19 on Friday. The company has a 50-day simple moving average of $12.14. Ventyx Biosciences has a twelve month low of $9.50 and a twelve month high of $26.00.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Citigroup Inc. bought a new stake in Ventyx Biosciences in the fourth quarter valued at about $56,000. California State Teachers Retirement System bought a new stake in Ventyx Biosciences in the fourth quarter valued at about $114,000. Wells Fargo & Company MN bought a new stake in Ventyx Biosciences in the fourth quarter valued at about $121,000. Deutsche Bank AG bought a new stake in Ventyx Biosciences in the fourth quarter valued at about $126,000. Finally, Parametric Portfolio Associates LLC bought a new stake in Ventyx Biosciences in the fourth quarter valued at about $217,000. 60.05% of the stock is currently owned by institutional investors and hedge funds.

About Ventyx Biosciences (Get Rating)

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus.

See Also